Abstract
Copyright: © 2012 Wang S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Pancreatic cancer is the fourth leading cause of cancer-related deaths in both men and women (preceded by lung, prostate/breast and colon-rectum) in the United States, with a 5-year survival rate of less than 5% [1]. Despite the rapid advances in diagnostic and operative techniques, the patient survival has little improvement in the last decade. Chemoresistance [2,3], early metastases, and late clinical presentation [4] are the major reasons for the poor clinical outcomes. This discouraging reality strongly suggests an urgent demand of new research directions and alternative/complementary approaches to improve the clinical outcome of pancreatic cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
